New research reveals that people who stop using blockbuster slimming jabs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who halt conventional lifestyle regimens.
Published data in a leading medical journal demonstrates that while obese people can lose substantial amounts of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these drugs need to be aware of the potential of fast weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about 18 months.
Comparing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, contrasted the effects of the injectable medications with older methods.
Scientists emphasize that people who shed pounds through lifestyle changes alone usually see a slower creep back—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Doctors propose the mechanism of the drugs accounts for the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the treatment is often ongoing.
This view is echoed by pharmaceutical companies, who note that the results "underscore the chronic character of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have stopped the medication explain a intense resurgence of cravings.
"It was like something that goes on and you're instantly ravenous," described one woman.
This challenge is worsened if individuals have not developed sustainable lifestyle or habit changes during treatment.
Significant Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated behavioural management.